Prophylactic ibuprofen does not improve pain with IUD insertion: a randomized trial. 
Introduction
Inconsistent use and discontinuation of contraceptives are major causes of unintended pregnancy [1] . The failure rate of the pill, patch or ring is 20 times higher than that of longacting reversible contraceptives (LARCs) [2] . Increasing acceptability and use of LARC methods like the intrauterine device (IUD) is an important strategy to reduce the risk of unintended pregnancy [3] .
Despite well-established safety and efficacy profiles, IUDs are still underutilized in the United States. Concerns about pain and difficulty with insertion are currently a major barrier to IUD use, especially among nulliparous women [4, 5] .
Although nonsteroidal antiinflammatory drugs (NSAIDs) are commonly used prior to IUD insertion to decrease pain, no data support the utility of this practice, including use specifically in nulliparous women [6, 7] . The largest trial of NSAIDs prior to IUD insertion used ibuprofen 400 mg, a dose lower than is commonly recommended in the United States [7] . Interestingly, NSAIDs are often recommended prior to other office-based gynecologic procedures, such as colposcopy [8] , endometrial biopsy [9] and dilation and curettage [10] [11] [12] , though data are mixed about their effectiveness with these procedures as well.
The goal of this study was to determine if ibuprofen 800 mg administered prophylactically prior to IUD placement reduces pain with the insertion procedure among U.S. nulliparous and multiparous women choosing either the copper T380A IUD or the LNG 52 mg IUS.
Materials and methods
This randomized, double-blind, placebo-controlled trial was conducted as a planned substudy of a multicenter trial evaluating IUD insertion following first-trimester uterine aspiration. Subjects were enrolled from June 2007 to February 2009 at four U.S. academic medical centers: Oregon Health and Science University, the University of Pittsburgh, Emory University and the University of New Mexico. The methods and outcomes of the main study have been previously described [13] . Briefly, women 18 years and older requesting a first-trimester uterine aspiration for induced or spontaneous abortion who also desired an IUD were enrolled in the main study. Each participant chose to receive an LNG 52 mg IUS (Mirena, Bayer HealthCare Pharmaceuticals) or a copper T380A IUD [ParaGard T380A; Teva Pharmaceuticals (formerly Duramed Pharmaceuticals)]; the diameters of the inserters were 4.75 mm and 4.5 mm, respectively. Subjects were randomized to insertion immediately following the aspiration procedure (immediate) or 2-6 weeks following the procedure (delayed). Women in the delayed insertion group who returned for the insertion procedure and did not have an allergy to ibuprofen or renal impairment were offered participation in this substudy. The institutional review boards of each institution approved the study protocol, and all study subjects gave written consent prior to enrollment.
Subjects in this substudy were randomized to receive ibuprofen 800 mg or placebo 30-45 min prior to IUD insertion. Randomization was performed using computergenerated blocks with varying sizes, stratified by center with equal allocation to the two treatment arms. Sequentially numbered opaque envelopes were prepared by study staff not involved in conducting the trial. The placebo and ibuprofen capsules were created to be identical in appearance and were prepared and packaged at a central site. The pharmacy dispensed the study medication based on the randomization scheme to ensure allocation concealment.
The IUD was inserted by an experienced study investigator, using the standard manufacturer approved technique for each IUD type, including placement of a tenaculum and uterine sounding. No cervical dilation or misoprostol was used for any IUD insertion in this study. Subjects rated their pain using a 100-mm visual analog scale (VAS) (anchors: 0=no pain, 100=worst imaginable) at the time of speculum insertion and immediately following deployment of the IUD (prior to cutting the threads). As this study was designed to specifically evaluate pain with the insertion process, pain assessments were not performed after the procedure and pain medication usage was not evaluated.
Statistical analyses
Several studies demonstrate that a change of 9-14 mm on a 100-mm VAS is a minimal clinically important difference in perceived pain that is reproducible among patients experiencing both mild and severe forms of pain [14] [15] [16] [17] . When designing this study, we anticipated that 266 women would be randomized to delayed IUD insertion in the main study and return for IUD insertion. Using a two-sample t test, this estimated sample size would provide 80% power at an alpha of 0.05 to identify a 7-mm difference on a 100-mm VAS assuming a standard deviation of 20 mm.
Baseline characteristics were compared according to treatment group to assess for significant differences using a Fisher's Exact Test, Chi-square test or t test where appropriate. To be consistent with common clinical reporting of VAS results to convey clinical relevance for average treatment effect, we compared mean VAS scores. A t test was used to evaluate the primary outcome, mean pain with IUD insertion measured on a 100-mm VAS. However, the data were not normally distributed; thus, we also report median scores. Univariate and multivariable mixed effects regression analyses were used to evaluate potential confounders and to determine independent predictors of insertional pain. All analyses were completed using SPSS (version 17.0) and SAS (version 9.2).
Results
A total of 222 women returned for their IUD insertion appointment, of which 3 had an allergy to NSAIDs and 7 had already taken pain medicine prior to the appointment, leaving 212 potential subjects. Of these, 202 were enrolled, with 101 randomized to ibuprofen and 101 randomized to placebo (Fig. 1 ). There were no significant differences in baseline characteristics between the two treatment groups (Table 1 ) or in the baseline pain reported with placement of the speculum (Table 2 ). All IUDs were placed successfully upon first attempt.
Overall, there was no significant difference in mean or median pain scores for IUD placement between women who received ibuprofen or placebo (Table 2) . Similarly, there was no significant difference in pain scores with IUD placement when only nulliparous or parous women were evaluated separately. Similar results were noted when evaluating median pain scores (Table 2) . A small number of parous women had no prior vaginal delivery, of whom 11 were in the ibuprofen group and 6 were in the placebo group. When pain with IUD insertion was evaluated for the population as a whole, median pain scores for the 17 women who were parous and had no vaginal delivery (median 56 mm, range 7-100; mean 53.9 mm, S.D. 27.4) were more similar to the nulliparous women (59.5 mm, range 0-100; mean 54.6 mm, S.D. 25.3) than the other parous women (median 29.0 mm, range 1-96; mean 32.1 mm, S.D. 23.2). All subjects reported a higher pain score following IUD insertion than with speculum placement.
Both parity and pain with speculum insertion were associated independently with IUD insertional pain in univariate analysis (both pb.0001). In multivariable analysis, only parity remained a strong predictor of pain, with pain decreasing in a linear pattern as parity increases from 0 to ≥ 3. There were no differences in pain scores based on age (p=.07), body mass index (p=.13), IUD-type (p=.62), history of dysmenorrhea (p=.35), previous IUD use (p=.62), number of days since aspiration (p=.31) or any sociodemographic characteristic listed in Table 1 .
Discussion
This trial demonstrated that ibuprofen 800 mg administered 30-45 min prior to IUD insertion does not decrease pain with the procedure among U.S. women receiving either an LNG 52 mg IUS or a copper T380A IUD. Additionally, no difference was found when the data were stratified by parity. Harms of providing a medication such as ibuprofen without evidence of benefit include elevated risk of side effects and anxiety about expected pain and increased complexity of scheduling.
Although we did not enroll the number of women originally estimated, the final sample still provided a strong ability to detect a difference; whereas the original sample size would have detected a difference in mean VAS scores of 7 mm, the final sample had 80% power to detect a difference of approximately 8 mm using a t test of proportions with an alpha of 0.05 (Power and Precision release 4.1). Moreover, the sample size of nulliparous women was sufficient to detect a difference of 14 mm in VAS score while that of parous women could detect a difference of 10 mm. We failed to enroll our expected sample size due to poor follow-up for interval IUD placement following first-trimester uterine aspiration, underscoring the desirability of immediate postabortion placement of an IUD [13] .
Nulliparous women in our study reported approximately twice as much pain with IUD insertion compared to multiparous women (approximately 60 mm versus 30 mm). Parous women who have not had a vaginal delivery appear to report similar pain to nulliparous women as opposed to parous women who have a prior vaginal delivery. These pain levels with IUD insertion are consistent with results from recent European and U.S. studies of other pain control interventions. A Swedish study evaluating misoprostol for IUD insertion among nulliparous women reported pain scores of 65-70 mm on a 100-mm VAS [18] . A Dutch study evaluating misoprostol with IUD insertion reported mean pain scores of 54-59 mm in nulliparous and 26-33 mm in multiparous women [19] . A U.S. study evaluating intracervical lidocaine for IUD insertion among 200 women reported mean pain scores of 61-62 mm in nulliparous and 43-48 mm in multiparous women [20] . Previous studies demonstrate similar pain scores between American nulligravid and nulliparous women who have had previous early pregnancies, as in our study [21, 22] . In contrast, pain levels with IUD insertion reported by Chilean women are comparably low for both groups {mean pain score on a 100-mm VAS of 28 mm [95% confidence interval (CI) 20-35 mm] for the nulliparous group and 20 mm (95% CI 18-21 mm) for the multiparous group} [7] . Accordingly, it appears that women in Chile experience less pain overall with IUD insertion compared to U.S. or European women.
The only predictor of pain that remained significant in our study with multivariable analysis was parity. In Chilean women, older age, nulliparity, nonlactation and less time since delivery (3 versus 6 months) were associated with higher levels of insertional pain. Additionally, time since last menses was associated with pain, with women 6-10 days since the start of last menses reporting significantly less mean pain (10 mm) than women less than 6 days or more than 10 days since last menses (18-19 mm) . U.S. and European studies evaluating IUD placement pain also demonstrate that parity and time since delivery are associated with pain. However, age, IUD-type and history of dysmenorrhea have shown conflicting results.
Our study did not address pain in the hours after placement. Although it is possible that some women who use ibuprofen or another NSAID before IUD placement may have decreased pain at in the hours following the procedure, these women could also use pain medicine as needed, removing a provision that all women take ibuprofen in advance of the procedure.
Strengths of our study are its power to evaluate effects for both nulliparous and multiparous women, the use of both devices approved in the U.S. during the study period and its double-blind, randomized design. In addition, the maximal dose of ibuprofen was evaluated. Limitations include that pain in the time period following IUD insertion was not evaluated. Also, we evaluated only one time point (30-45 min) for drug absorption. We picked this point because time to pain relief after ingesting ibuprofen has been reported to be in this range [23, 24] and to reflect a realistic interval for administration in an office setting. However, it may require as much as 2 h for ibuprofen to reach maximal effective blood levels [25] .
The IUDs used in this trial were the only two available at the time. Products recently introduced include a new IUD (LNG 13.5 mg IUS; Skyla, Bayer Healthcare) with a smaller insertion diameter, as well as a new inserter for the LNG 52 mg IUS with a slightly smaller diameter (4.25 mm). Smaller inserters may reduce discomfort but it is not likely that these will alter our conclusion of a lack of benefit of ibuprofen. Women choosing an IUD for contraception have the highest continuation and satisfaction rates compared to other contraceptive methods [26] . In recent years, IUD use has risen predominately among parous women [27] , and as our study confirmed low pain levels with IUD insertion among parous women, likely no additional pain intervention is necessary for this group. However, reducing pain with IUD insertion among nulliparous women may increase the acceptability of this highly effective contraceptive method for this group. NSAIDs, intracervical lidocaine [28] , nitric oxide donors [21, 22] and misoprostol [29] have all been studied, but none have been shown to be effective. Given the important public health need to reduce barriers to IUD utilization overall, further investigations should concentrate on alternate strategies to reduce pain and improve satisfaction with IUD insertion among nulliparous women.
